Insmed Shares Are Trading Higher After Announcing That No Agreement Was Reached Between the Company and AstraZeneca and Insmed Retains Full Worldwide Development and Commercialization Rights for Brensocatib in All Indications Other Than COPD or Asthma...
Insmed Shares Are Trading Higher After Announcing That No Agreement Was Reached Between the Company and AstraZeneca and Insmed Retains Full Worldwide Development and Commercialization Rights for Brensocatib in All Indications Other Than COPD or Asthma...
Insmed股份交易上漲，宣佈公司與阿斯利康未達成任何協議，Insmed在COPD或哮喘之外的所有適應症中保留Brensocatib的全球開發和商業化權利。
Insmed Shares Are Trading Higher After Announcing That No Agreement Was Reached Between the Company and AstraZeneca and Insmed Retains Full Worldwide Development and Commercialization Rights for Brensocatib in All Indications Other Than COPD or Asthma Development.
Insmed股票價格上漲，宣佈公司與阿斯利康未能達成協議，Insmed將保留Brensocatib在除COPD或哮喘發展以外所有適應症的全球開發和商業化權利。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。